Andrew Cooper
Stock Analyst at Raymond James
(3.26)
# 1,093
Out of 5,112 analysts
151
Total ratings
47.01%
Success rate
2.26%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AZTA Azenta | Maintains: Outperform | $35 → $45 | $34.50 | +30.43% | 3 | Nov 25, 2025 | |
| ITGR Integer Holdings | Reiterates: Outperform | $143 → $95 | $78.52 | +20.99% | 4 | Oct 24, 2025 | |
| HOLX Hologic | Downgrades: Market Perform | n/a | $74.94 | - | 13 | Oct 22, 2025 | |
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $11.07 | +44.53% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $79.90 | -2.38% | 10 | Aug 11, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $97.10 | -37.18% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $96.26 | +19.47% | 9 | Jul 29, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $562.39 | -4.87% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $6.70 | +49.25% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $28.06 | -10.91% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $224.86 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $224.35 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $101.38 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.19 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $224.74 | -62.18% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $28.32 | +168.36% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.80 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.68 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $42.04 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.45 | - | 5 | Sep 22, 2021 |
Azenta
Nov 25, 2025
Maintains: Outperform
Price Target: $35 → $45
Current: $34.50
Upside: +30.43%
Integer Holdings
Oct 24, 2025
Reiterates: Outperform
Price Target: $143 → $95
Current: $78.52
Upside: +20.99%
Hologic
Oct 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $74.94
Upside: -
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $11.07
Upside: +44.53%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $79.90
Upside: -2.38%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $97.10
Upside: -37.18%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $96.26
Upside: +19.47%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $562.39
Upside: -4.87%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $6.70
Upside: +49.25%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $28.06
Upside: -10.91%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $224.86
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $224.35
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $101.38
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $19.19
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $224.74
Upside: -62.18%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $28.32
Upside: +168.36%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.80
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.68
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $42.04
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.45
Upside: -